Trial Profile
An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Losartan (Primary)
- Indications COVID-19 respiratory infection; Respiratory insufficiency
- Focus Adverse reactions
- 02 Nov 2020 Status changed from recruiting to completed.
- 08 Apr 2020 New trial record